Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma.

ABSTRACT:

Introduction

Systemic therapy for advanced renal cell carcinoma (aRCC) has become increasingly diverse. In the 1st-line setting, various combination therapies are available, with little comparative data on the efficacy of the therapies. The aim of this study was to compare the current 1st-line combination therapies under real-life conditions and to investigate risk factors in the patient population.

Methods

Patients with aRCC who started 1st-line IO/IO or IO/TKI combination  therapy between 03/2019 and 10/2023 were included. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were time on treatment (ToT), duration of response (DoR), subsequent therapies, the evaluation of risk factors and their influence on PFS and OS. Su

SUBMITTER: Haack M 

PROVIDER: S-EPMC11923313 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature